scholarly journals Population Analysis of Pharmacogenetic Polymorphisms Related to Acute Lymphoblastic Leukemia Drug Treatment

2012 ◽  
Vol 32 (4) ◽  
pp. 247-253 ◽  
Author(s):  
Marcela A. Chiabai ◽  
Tulio C. L. Lins ◽  
Robert Pogue ◽  
Rinaldo W. Pereira
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Drug Response ◽  
Population Analysis ◽  
Lymphoblastic Leukemia ◽  
European Population ◽  
Brazilian Population ◽  
Genetic Ancestry ◽  
Significant Differentiation ◽  
Amova Analysis ◽  
Hapmap Populations

This study aimed to evaluate in the Brazilian population, the genotypes and population frequencies of pharmacogenetic polymorphisms involved in the response to drugs used in treatment of acute lymphoblastic leukemia (ALL), and to compare the data with data from the HapMap populations. There was significant differentiation between most population pairs, but few associations between genetic ancestry and SNPs in the Brazilian population were observed. AMOVA analysis comparing the Brazilian population to all other populations retrieved from HapMap pointed to a genetic proximity with the European population. These associations point to preclusion of the use of genetic ancestry as a proxy for predicting drug response. In this way, any study aiming to correlate genotype with drug response in the Brazilian population should be based on pharmacogenetic SNP genotypes.

scholarly journals Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Blood ◽  
2017 ◽  
Vol 129 (11) ◽  
pp. e26-e37 ◽  
Author(s):  
Viktoras Frismantas ◽  
Maria Pamela Dobay ◽  
Anna Rinaldi ◽  
Joelle Tchinda ◽  
Samuel H. Dunn ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Drug Response ◽  
Ex Vivo ◽  
Lymphoblastic Leukemia ◽  
Drug Repurposing ◽  
Therapeutic Agents ◽  
Drug Resistant ◽  
Key Points

Key Points Ex vivo drug profiling captures disease-relevant features and relevant sensitivity to therapeutic agents in ALL. A subset of drug-resistant T-ALL without mutations in ABL1 is highly responsive to dasatinib, which provides a rationale for drug repurposing.

Relating genomic variation to drug response in childhood acute lymphoblastic leukemia by multiplexed targeted sequencing

2010 ◽  
Vol 11 (Suppl 1) ◽  
pp. P41
Author(s):  
Agata Wesolowska ◽  
Marlene D Dalgaard ◽  
Louise Borst ◽  
Laurent Gautier ◽  
Mads Bak ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Drug Response ◽  
Lymphoblastic Leukemia ◽  
Genomic Variation ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Targeted Sequencing

scholarly journals Banding cytogenetic analysis in pediatric patients with acute lymphoblastic leukemia (ALL) in a Brazilian population

2013 ◽  
Vol 6 (1) ◽  
pp. 37 ◽  
Author(s):  
Erica Aires Gil ◽  
Tirzah Braz Petta Lajus ◽  
Taissa Maria Oliveira de Moura ◽  
Juliana Mendonça Freire ◽  
Andréa Luciana Araújo da Fernandes ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Cytogenetic Analysis ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
Brazilian Population
Sign in / Sign up

Export Citation Format

Share Document